Abstract
KNI-272, a conformationally constrained human immunodeficiency virus (HIV) protease inhibitor containing a P1 allophenylnorstatine (Apns) ((2S,3S)- 3-amino-2-hydroxy-4-phenylbutyric acid), has been shown to be a selective and potent inhibitor of the replication of a wide spectrum of HIV strains in vitro. When KNI-272 was tested in combination with 3'-azido-2',3'-dideoxythymidine (AZT) or 2',3'-dideoxyinosine (ddI) against a primary HIV-1 isolate in phytohemagglutin-activated peripheral blood mononuclear cells (PHA-PBM), its activity was identified to be additive, but not synergistic or antagonistic, as analyzed with the COMBO program package. When tested alone for anti-HIV-1 activity in resting PBM (R-PBM) and PHA-PBM, KNI-272 was found to be comparably potent against the virus in both target cell populations, whereas AZT was more potent in PHA-PBM than in R-PBM and ddI was more potent in R-PBM. These data suggest a potential clinical application of KNI-272 and its analogs.
References
Mar 1, 1992·Journal of Virology·J A ZackI S Chen
Aug 1, 1992·Journal of Virology·H JacobsenJ Mous
May 1, 1992·Antimicrobial Agents and Chemotherapy·S KageyamaH Mitsuya
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P AshornE A Berger
Sep 1, 1991·Chemical & Pharmaceutical Bulletin·T MimotoH Sakikawa
Oct 18, 1991·Science·M I BukrinskyM Stevenson
Jan 1, 1990·Annals of the New York Academy of Sciences·J N WeinsteinJ Szebeni
Aug 3, 1990·Science·J EricksonN Wideburg
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·R L DesJarlaisC S Craik
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P AshornB Moss
Apr 20, 1990·Cell·J A ZackI S Chen
Oct 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·H MitsuyaS Broder
Mar 31, 1989·Science·B A LarderD D Richman
Dec 1, 1989·Science·B A Larder, S D Kemp
Mar 1, 1989·The Journal of Experimental Medicine·C F PernoS Broder
Mar 15, 1986·Lancet·R YarchoanD W Barry
Jul 23, 1987·The New England Journal of Medicine·M A FischlR T Schooley
Dec 1, 1993·Antiviral Research·E L WhiteW M Shannon
Aug 1, 1993·Antiviral Research·D M LambertS R Petteway
May 1, 1995·The Journal of Infectious Diseases·E KojimaH Mitsuya
Jan 1, 1994·The Journal of Infectious Diseases·R YarchoanH Mitsuya
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·S D MalleyJ R Vila
Jun 1, 1994·AIDS Research and Human Retroviruses·S KageyamaH Mitsuya
Feb 1, 1994·Journal of Virology·K NagyS Oroszlan
Oct 15, 1993·Annals of Internal Medicine·A C CollierL Corey
Jan 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T ShirasakaH Mitsuya
May 1, 1993·The Journal of Clinical Investigation·W Y GaoH Mitsuya
Jan 1, 1993·Antimicrobial Agents and Chemotherapy·J J KortG L Drusano
Apr 1, 1993·Antimicrobial Agents and Chemotherapy·S KageyamaH Hayashi
Citations
May 13, 1999·Antiviral Research·R W HumphreyR Yarchoan
Oct 1, 1993·Antimicrobial Agents and Chemotherapy·E AlteriP Schneider
Oct 12, 1999·Journal of Clinical Pharmacology·S HayashiF Aweeka
Jul 14, 1998·Antimicrobial Agents and Chemotherapy·B U MuellerF M Balis
May 1, 1997·Antimicrobial Agents and Chemotherapy·D LamarreP C Anderson